Segal Trials Recognized for Exceptional Enrollment in Landmark Schizophrenia Study
Miami Lakes, FL – Segal Trials, a leading clinical research organization specializing in acute schizophrenia trials, has been recognized by the PPD Select Global Partnership Program for outstanding enrollment performance. This accolade was awarded for the site’s exemplary participation in the Phase 2 study of CVL-231 (Emraclidine), aimed at treating patients experiencing an acute exacerbation of psychosis.
Dr. Rishi Kakar, the research site’s Principal Investigator, and a respected figure in the field of psychiatry, led the initiative, meeting and often exceeding the enrollment expectations set forth by the program. "Our team's dedication to advancing the treatment of schizophrenia through cutting-edge research and patient-centered care has made this achievement possible,” stated Dr. Kakar. “Our success in the CVL-231 study underscores our commitment to finding better treatments for those affected by this challenging condition."
Segal Trials Miami Lakes Inpatient Site, known for its state-of-the-art facilities and patient-first approach, played a crucial role in the study’s success. The site utilized innovative outreach strategies and community partnerships to connect with potential participants, showcasing their ability to effectively reach and engage patients in critical research.
“We are proud of our continuous success in exceeding enrollment targets in acute schizophrenia research,” said a Segal Trials Exec. “We can provide a list of studies that exemplify our consistent performance and expertise in this therapeutic area. Our achievements are a testament to our operational excellence and the trust we have built within the psychiatric community.”
Schizophrenia affects approximately 1% of the global population, with many individuals experiencing episodes of acute psychosis that significantly impact their quality of life. Current treatment options, while effective for many, leave a significant portion of the patient population underserved, highlighting the urgent need for innovative therapeutic alternatives like CVL-231.
For more information about Segal Trials and their contributions to schizophrenia research, please visit Enrolling Studies - Segal Trials
About Segal Trials
Segal Trials is a leading clinical research organization specializing in the study of psychiatric and neurological conditions. Founded in 1998, Segal Trials operates multiple state-of-the-art facilities in South Florida, dedicated to high-quality clinical trials aiming to advance medical science and improve patient outcomes.
